Lucinactant contains the peptide sinapultide (KL4 acetate, KLLLLKLLLLKLLLLKLLLLK), dipalmitoylphosphatidylcholine, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (as the sodium salt), and palmitic acid.
CAT No: 10-101-341
CAS No:1802925-00-3
Synonyms/Alias:L-Lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysine, acetate; Sinapultide acetate
Chemical Name:acetic acid;(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]hexanoic acid
Lucinactant is a synthetic peptide-based surfactant that has garnered significant attention in the field of pulmonary research due to its unique structural and functional properties. Engineered to mimic the activity of endogenous pulmonary surfactant, it incorporates a synthetic peptide analog of surfactant protein B (SP-B) within a phospholipid matrix, offering a biochemically defined alternative to animal-derived surfactants. Its well-characterized composition and reproducible performance make it an important tool for investigating the molecular mechanisms of surfactant function, surfactant-protein interactions, and the physicochemical basis of alveolar stability. As a research-use compound, lucinactant provides a robust platform for studies aiming to elucidate the roles of surfactant components in respiratory physiology and pathology.
Pulmonary surfactant research: In laboratory settings, lucinactant serves as a model system for dissecting the biophysical and biochemical properties of pulmonary surfactant. Researchers utilize it to study surface tension-lowering mechanisms at the air-liquid interface of alveoli, enabling detailed analysis of how synthetic peptides and phospholipids interact to stabilize lung architecture. Its defined composition facilitates controlled experimental designs, allowing for precise evaluation of surfactant activity under various physiological and pathophysiological conditions.
Surfactant protein studies: The inclusion of a synthetic SP-B peptide analog in lucinactant makes it a valuable resource for exploring the specific contributions of surfactant proteins to overall surfactant function. Investigators employ it to examine the role of SP-B in lipid organization, vesicle fusion, and the formation of functional surfactant films. This application is particularly relevant for understanding the molecular determinants of surfactant efficacy and for differentiating the effects of protein composition from those of lipid components.
Formulation development: Lucinactant is extensively used in the development and optimization of synthetic surfactant formulations. Its reproducible properties allow formulation scientists to systematically modify lipid and peptide constituents, assess their impact on surfactant performance, and benchmark novel candidates against a well-characterized reference. This supports the advancement of next-generation surfactant products and informs the design of biomimetic materials for pulmonary delivery systems.
Respiratory toxicology models: In toxicological research, lucinactant provides a standardized surfactant system for evaluating the impact of inhaled substances, particulates, or environmental toxins on surfactant function. By incorporating it into in vitro or ex vivo lung models, researchers can monitor surfactant inhibition, biophysical disruption, and recovery processes in response to toxic exposures, thereby gaining insight into mechanisms of respiratory injury and defense.
Analytical method validation: The defined nature of lucinactant makes it an ideal reference material for the development and validation of analytical techniques targeting surfactant components. Analytical chemists employ it in the calibration of assays measuring phospholipids, surfactant proteins, and surface activity, ensuring methodological accuracy and reproducibility. Its use enhances the reliability of quantitative and qualitative assessments in surfactant research, supporting both basic and applied investigations.
1. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy
3. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists
5. High fat diet and GLP-1 drugs induce pancreatic injury in mice
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More